It is well-, and widely- known that tuberculosis is a persistent high burden disease in much of the lower income geographies around the globe. So this is quintessentially "doing good, after doing well" -- at Merck. Here's the latest:
. . .Under the agreement, Merck granted the Gates MRI an exclusive global license for MK-7762 and MK-3854.
“At Merck we have a proud legacy of addressing some of the world’s most challenging infectious diseases,” said Dr. Dean Y. Li, president, Merck Research Laboratories. “With the expertise and capabilities of the Gates MRI, MK-7762 and MK-3854 are positioned for rigorous evaluation of their potential as components of novel TB treatment regimens. . . .”
Dr. Li added that Gates MRI will undertake non-clinical and clinical studies of the candidates to evaluate their potential in new affordable combination treatment regimens for TB with the aim of shortening treatment duration irrespective of resistance to current TB drugs. . . .
Onward, smiling -- finding Taco Tuesdays, and my favorite truck vendors later today in the steel and glass canyons, as we had our first snowfall here overnight. . . whoosh. . . .
नमस्ते
No comments:
Post a Comment